(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Ever Wonder What An EV Motorcycle Water Crossing Would Be Like? Here You Go - 2The Response Uncovered: Disentangling the Secrets of the Universe
- 3Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- 4The most effective method to Promoter for Cutthroat Medical attendant Compensations in Your Medical services Office
- 5The Best Web-based Courses for Ability Advancement
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Somaliland denies trading recognition with Israel for accepting Gazans
- Manual for Purchasing a Modest Jeep Wrangler for Seniors
- The Best Business visionaries Under 30
- Civilian toll mounts in Iran as war presses on
- Rights group: At least 2,500 deaths during protest crackdown in Iran
- Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
- Share your number one city visit transport that leaves a mark on the world wake up!
- Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
